Latest News about IBB
Recent news which mentions IBB
   The Week Ahead In Biotech (March 6-12): Quiet Week On Tap With Earnings Season Reaching It Final Leg
   
  
  
  March 06, 2022
  From Benzinga
 From Benzinga
 From Benzinga
 From Benzinga
 From Benzinga
 From Benzinga
 
   The Week Ahead In Biotech (Feb. 27-March 5): Earnings, Multiple Regulatory Decisions Take The Spotlight
   
  
  
  February 27, 2022
  From Benzinga
 
   The Daily Biotech Pulse: Lilly's Jardiance Gets Nod For Heart Failure, Pulmatrix Announces Reverse Split, Reata Awaits FDA Decision
   
  
  
  February 25, 2022
  From Benzinga
 
   The Daily Biotech Pulse: Orphazyme Plunges On Regulatory Setback In Europe, Pulmonx Earnings Disappoint, Amicus Declines To Spin Off Genetic Medicine Company
   
  
  
  February 24, 2022
  From Benzinga
 
   The Daily Biotech Pulse: Kodiak Sinks On Adverse Study Outcome, Marinus Flags Delay In Clinical Trial, Mainz Biomed Gains On Positive Regulatory Development
   
  
  
  February 23, 2022
  From Benzinga
 
   The Week Ahead In Biotech (Feb. 20-26): Reata Awaits FDA Decision, Bausch Health, Moderna Lead Earnings News Flow
   
  
  
  February 20, 2022
  From Benzinga
 
   The Daily Biotech Pulse: Regeneron-Sanofi Halt Late-Stage Dupixent Study, Agios Gets FDA Nod, Safety Scare For GSK's RSV Vaccine, Shockwave Jumps On Earnings
   
  
  
  February 18, 2022
  From Benzinga
 
   Get Ready for a Biotech ETF Comeback
   
  
  
  February 17, 2022
  From ETF Trends
 
   The Daily Biotech Pulse: J&J Unit Announces Research Collaboration With Remix, Regencell Touts COVID Data, Decision Day For Agios
   
  
  
  February 17, 2022
  From Benzinga
 
   The Daily Biotech Pulse: Avenue Tumbles On Negative Adcom Verdict, Moderna's Expanded Deal With Rovi, Gilead Takes Equity Stake In Hookipa
   
  
  
  February 16, 2022
  From Benzinga
 
   The Daily Biotech Pulse: Larimar Plunges On Extension Of Clinical Hold, ImmunityBio Gains On Positive Data, Adcom Test Awaits Avenue Therapeutics
   
  
  
  February 15, 2022
  From Benzinga
 
   The Week Ahead In Biotech (Feb. 13-19): Agios FDA Meeting, Avenue Adcom, Earnings And More
   
  
  
  February 13, 2022
  From Benzinga
 
   The Daily Biotech Pulse: Adcom Recommends Additional Trials For Lilly's Partnered Cancer Drug, Novavax Touts Pediatric Vaccine Data, TC Biopharm IPO
   
  
  
  February 11, 2022
  From Benzinga
 
   The Daily Biotech Pulse: AstraZeneca Q4 Gets COVID Boost, Seagen Plunges On Earnings, Adcom Test Awaits Lilly
   
  
  
  February 10, 2022
  From Benzinga
 
   The Daily Biotech Pulse: Bristol-Myers Squibb Announces $5B Accelerated Buyback, Qiagen Reaps COVID Testing Windfall, WORLDSymposium Presentations Kick In
   
  
  
  February 09, 2022
  From Benzinga
 
   Biotech ETFs Muddled Despite Amgen Strength
   
  
  
  February 08, 2022
  From ETF Trends
 From Benzinga
 
   The Week Ahead In Biotech (Feb. 6-12): Pfizer, AstraZeneca Earnings, Conference Presentations, IPOs And More
   
  
  
  February 06, 2022
  From Benzinga
 
   The Daily Biotech Pulse: Sanofi, Bristol-Myers Squibb Gain On Earnings, Valneva-Pfizer Tout Positive Lyme Disease Vaccine Data, UNITY Biotech Restructures
   
  
  
  February 04, 2022
  From Benzinga
 
   The Daily Biotech Pulse: Big Pharma Earnings Prove Lackluster, Mersana Inks $1B ADC R&D Deal, Syros Gets Orphan Drug Designation
   
  
  
  February 03, 2022
  From Benzinga
 
   The Daily Biotech Pulse: LogicBio Genome Editing Therapy Study Placed On Clinical Hold, Gilead Q4 Disappoints On Slowing Veklury Sales
   
  
  
  February 02, 2022
  From Benzinga
 
   Small-Cap Biotech Opportunity Knocks
   
  
  
  February 01, 2022
  From ETF Trends
 
   CNBC's Final Trades: NXP Semiconductors, Qualcomm, Deere And This Way To Gain Exposure To Growth Potential
   
  
  
  February 01, 2022
  From Benzinga
 
   Attention Biotech Investors: Mark Your Calendar For These Key February PDUFA Dates
   
  
  
  February 01, 2022
  From Benzinga
 
   Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
  
  
 Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
  © 2025 FinancialContent. All rights reserved.
 
